within Pharmacolibrary.Drugs.N_NervousSystem.N06A_Antidepressants.N06AX29_Brexanolone;

model Brexanolone
  extends Pharmacolibrary.Drugs.ATC.N.N06AX29;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>N06AX29</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Brexanolone is a neuroactive steroid and a positive allosteric modulator of GABA-A receptors, used for the treatment of postpartum depression in adult women. It is currently FDA-approved for this indication and is administered as an intravenous infusion.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult women with postpartum depression following the recommended clinical intravenous dosing regimen.</p><h4>References</h4><ol><li><p>DeBattista, C, &amp; Schatzberg, AF (2024). The Black Book of Psychotropic Dosing and Monitoring. <i>Psychopharmacology bulletin</i> 54(3) 8–59. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38993656/\">https://pubmed.ncbi.nlm.nih.gov/38993656</a></p></li><li><p>Leader, LD, et al., &amp; VandenBerg, A (2019). Brexanolone for Postpartum Depression: Clinical Evidence and Practical Considerations. <i>Pharmacotherapy</i> 39(11) 1105–1112. DOI:<a href=\"https://doi.org/10.1002/phar.2331\">10.1002/phar.2331</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31514247/\">https://pubmed.ncbi.nlm.nih.gov/31514247</a></p></li><li><p>Scott, LJ (2019). Brexanolone: First Global Approval. <i>Drugs</i> 79(7) 779–783. DOI:<a href=\"https://doi.org/10.1007/s40265-019-01121-0\">10.1007/s40265-019-01121-0</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31006078/\">https://pubmed.ncbi.nlm.nih.gov/31006078</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Brexanolone;
